I’ve recently joined the JAMA Network after a brief career in pharmaceutical editing, where I’ve read everything from the easy-to-digest pamphlets that come with your prescription to the headache-inducing instructions chemists follow when testing that a drug meets its quality compliance requirements.

One of these jobs required the terrifying task that editors, after editing an assignment, would sit together and read aloud entire monographs and articles to confirm all changes.

Real talk: I love editing because I get to read alone all day. I avoid public speaking whenever possible. Mustering the courage to read aloud in front of other people for hours on end—let alone pronounce words I’d never seen before—really revved the ol’ anxiety engine.

After countless sessions of tripping over impossible-to-say generic (or nonproprietary) drug names, I finally decided to do some research on my multisyllabic angst inducers.

Enter the United States Adopted Names (USAN) Council, a team composed of representatives from the American Medical Association, the United States Pharmacopeia, and the American Pharmacists Association, as well as a US Food and Drug Administration liaison and 1 member-at-large. This team “is responsible for selecting simple, informative, and unique nonproprietary (generic) drug names,” according to its website.

“Simple,” they say?

But, in fact, the names are not as daunting as I once thought and are often broken down into a general pattern. Again, from the USAN Council website:

Prefix: Means nothing; differentiates drug from others in class

(See? Nothing to be scared of here.)

Infix: Used occasionally; further subclassifies

Stem: Indicates place in nomenclature scheme; drugs with the same stem are related

(The stem is considered the pharmacologic family name and can be broken into further subgroups.)

 An example:

Cobimetinib

Prefix: co-

Infix: -bi-

Stem: -tinib (meaning: tyrosine kinase inhibitors [anticancer drug])

Stem subgroup: -metinib (meaning: MEK inhibitor [anticancer drug specifically to treat melanoma])

It also helps that the USAN Council strives to place any new drug into already existing families, so once you’ve seen several drugs in that family, pronouncing their siblings should be a breeze.

Next up for me: Conquering my Dorland’s Illustrated Medical Dictionary. Wish me luck!—Jamie Scott